Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
IPO Year: 2014
Exchange: NASDAQ
Website: xenon-pharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $60.00 | Outperform | Wolfe Research |
| 9/3/2025 | $48.00 | Overweight | Wells Fargo |
| 5/7/2025 | $55.00 | Buy | Chardan Capital Markets |
| 2/11/2025 | $67.00 | Buy | Deutsche Bank |
| 10/10/2024 | $50.00 | Outperform | Raymond James |
| 10/1/2024 | $53.00 | Buy | H.C. Wainwright |
| 1/4/2024 | $62.00 | Buy | Citigroup |
| 12/8/2023 | $63.00 | Outperform | Robert W. Baird |
| 10/24/2023 | Overweight | Cantor Fitzgerald | |
| 4/25/2023 | $58.00 | Overweight | Cantor Fitzgerald |
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
FWP - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
424B5 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
424B5 - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
10-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
SCHEDULE 13G - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
Fastest customizable press release news feed in the world
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded w
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offer
X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information: Date:Monday, March 9, 2026 Time:8:00 am ET (5:00 am PT) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:78
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xenon's next investor call to be held for X-TOLE2 topline data readout VANCOUVER, British Columbia and BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasda
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline data in MDD expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercializati
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. Company Presentation Details: Date:Monday, January 12, 2026 Time:9:00-9:40am Pacific Time (12:00-12:40pm Eastern Time) Webcast:Webcast - 44th Annual J.P. Morgan Healthcare Conference Presenter:Ian Mortimer, President and Chief Executive Officer,
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner, even in patients with difficult-to-treat diseaseFour real-world study posters illustrate significant burden of depression and ASM titration on people living with epilepsy; poster on impact of depression on outcomes and treatment patterns in patients with newly diagnosed epilepsy highlighted in AES press programNew pre-clinical data in Dravet syndrome suggest potential to improve motor function through NaV1.
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research initiated coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $60.00
Wells Fargo resumed coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $48.00
Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00
Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00
Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00
H.C. Wainwright initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $53.00
Citigroup initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $62.00
Robert W. Baird initiated coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $63.00
Cantor Fitzgerald resumed coverage of Xenon Pharmaceuticals with a rating of Overweight
Cantor Fitzgerald initiated coverage of Xenon Pharmaceuticals with a rating of Overweight and set a new price target of $58.00
Live finance-specific insights
X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared to -34.6% in 25 mg group in X-TOLEAzetukalner was generally well-tolerated with a safety profile consistent with X-TOLE studyXenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026X-TOLE2 data to be featured in Late Breaking Science oral presentation at AAN Annual Meeting in AprilCompany to host conference call and webcast today at 8:00
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026. Conference Call/Webcast Information: Date:Monday, March 9, 2026 Time:8:00 am ET (5:00 am PT) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:78
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing thera
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date:Monday, November 3, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference I
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercializ
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, August 11, 2025. Conference Call/Webcast Information: Date: Monday, August 11, 2025Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Webcast: Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID: 4102397 A live webcas
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, anticipated in Q3 2025 – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-foc
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information: Date:Monday, May 12, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:5532604 A live webcast of t
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference Call/Webcast Information: Date:Thursday, February 27, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:8120798 A live webcast of the company pre
This live feed shows all institutional transactions in real time.
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
Live Leadership Updates
VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and member of the Xenon senior executive team. Mr. Kelly is a proven executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the Company prepare for the anticipated commercialization of its lead candidate, azetukalner. Azetukalner is currently being studi
VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Mr. Cline will lead commercial strategy and operations for the Company's portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy. Azetukalner is currently being studied in Phase 3 trials for the trea
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide strategic leadership and oversight of the planning and execution for Xenon's legal function on a global basis. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are very pleased to welcome Andrea to Xenon's senior leadership team in the newly created role of Chief Legal Officer. Andrea joins us at a time when we have multiple late-stage clinical programs underway with the
BURNABY, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenon's portfolio of neurology-focused therapeutic programs. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are thrilled to welcome Chris to the Xenon senior leadership team as we enter an important period with multiple mid- to late-stage programs advancing within our neurology pipeline and continue
Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 Phase 3 XEN496 “EPIK” Clinical Trial Initiated in Patients with KCNQ2-DEE, a Rare Orphan Pediatric Disease BURNABY, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of th